Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 2997-3002, 2011.
Article
in En
| WPRIM
| ID: wpr-292765
Responsible library:
WPRO
ABSTRACT
<p><b>BACKGROUND</b>A phase III trial involving docetaxel, cisplatin, and fluorouracil (DCF) in the treatment of advanced gastric cancer was shown to have superior efficacy compared to cisplatin and fluorouracil alone, but with a high rate of hematologic toxicity. To reduce toxicity while maintaining the efficacy of DCF, we reduced the doses of docetaxel (D) and cis-platinum (CDDP), and administered 5-fluorouracil (5-FU) via a continuous intravenous (CIV) infusion.</p><p><b>METHODS</b>Chemotherapy-naive patients with gastric adenocarcinomas received D (60 mg/m(2) 1 hour on day 1), CDDP (30 mg/m(2) on days 1 and 2), and 5-FU (1500 mg×m(-2)×24 h(-1) CIV on days 1 and 8 every 3 weeks). The primary endpoint was the response rate.</p><p><b>RESULTS</b>Fourteen patients were enrolled. Based on the efficacy evaluation following at least 2 cycles of treatment, there was 7.1% complete remission (CR), 71% partial remission (PR), 14% stable disease (NC/SD), and 7.1% progressive disease (PD). The median survival time was 13 months. Nine patients (64%) had grade III-IV neutropenia, and 4 patients (29%) had grade IV neutropenia, among whom 1 had grade IV neutropenia with grade III nausea and vomiting.</p><p><b>CONCLUSION</b>The modified DCF regimen is highly active and has a favorable toxicity profile in Chinese patients with gastric cancer.</p>
Full text:
1
Database:
WPRIM
Main subject:
Stomach Neoplasms
/
Adenocarcinoma
/
Antineoplastic Combined Chemotherapy Protocols
/
Cisplatin
/
Taxoids
/
Therapeutic Uses
/
Drug Therapy
/
Fluorouracil
/
Antimetabolites, Antineoplastic
/
Antineoplastic Agents
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Chinese Medical Journal
Year:
2011
Document type:
Article